scholarly journals CLINICAL AND ECONOMIC ASPECTS OF HORMONOTHERAPY ER (+) HER2 (–) BREAST CANCER (BC): FOCUS ON AROMATASE INHIBITORS (AI)

2021 ◽  
pp. 86-92
Author(s):  
O. Ya. Mishchenko ◽  
Yu. I. Greshko ◽  
V. F. Ostashko ◽  
A. V. Berezniakov
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Retrospective Analysis ◽  
Aromatase Inhibitors ◽  
Pharmaceutical Market ◽  
Economic Aspects ◽  
Upward Trend ◽  
Aim Analysis ◽  
Market Prices ◽  
Her2 Breast Cancer

Aim. Analysis of clinical efficacy of AI for therapy ER (+) HER2 (–) BC, assortment and volume of their consumption in Ukraine in 2017–2020. Materials and methods. Analysis of the assortment and prices and consumption of AI for hormone therapy ER (+) HER2 (–) BC, available on the pharmaceutical market of Ukraine in 2017–2020. Results. A retrospective analysis of the assortment, prices and consumption of AI used for therapy ER (+) HER2 (–) BC, presented on the Ukrainian pharmaceutical market in 2017–2020, was carried out. AI were represented by 3 INNs: anastrozole (L02B G03), letrozole (L02B G04) and exemestane (L02B G06). Market prices in 2017 range from 460.5 to 4163.8; in 2018 – from 486.3 to 1849.0; in 2019 – from 308.7 to 1677.0; and in 2020 – from UAH 449.6 to UAH 2545.3. IA implemented in 2017 – 55,943, in 2018 – 81,284, in 2019 – 126,628, and in 2020 – 160,858.4 thousand packages. Conclusion. There is a clear tendency towards stabilization and even a decrease in prices for AI, if we compare the indicators of 2017 and 2020. There is a clear upward trend in consumption AI are implemented mainly of import production. The price picture for AI has changed somewhat due to the registration of drugs from the letrozole group in 2019-2020, and in 2020 – from the exemestane group.

Variation in prognostic factors in hormone receptor-positive breast cancer patients who responded to hormonal therapy and those who did not: A retrospective analysis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11514-11514
Author(s):  
A. Jain ◽  
P. Bapsy ◽  
S. V. Attili ◽  
U. Batra ◽  
L. Dasappa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Hormone Therapy ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Initial Diagnosis ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive ◽  
Hormonal Manipulation

11514 Background: Hormone receptor positive patents historically had a better prognosis than their receptor negative counterparts when other parameters are balanced. However not all the patients expressing Estrogen and progesterone respond well to the hormonal manipulation. Therefore we thought of doing a retrospective analysis of our hospital data to find out the differences in the prognostic factors in therapy responders and non responders. Methods: The study was conducted at tertiary care cancer center from India. Between 2002–2003 a total of 120 breast cancer patients who expressed either Estrogen receptor (ER) or progesterone receptor (PR) were analyzed. Only patients with metastatic breast cancer were analyzed. The patients were treated with our standard institutional protocol at the beginning according to the stage of the disease. The details and baseline characters were shown in table . Results: The responders tend to be post menopausal, having low grade, node negative tumors, expressed both ER and PR, and had long interval from the date of initial diagnosis. However tumor size and the site of metastasis (visceral vs. non visceral) did not alter the outcome to hormone therapy. Conclusion: patients who are having higher age, lower tumor grade, lower number of nodes, longer disease free interval after adjuvant therapy and expressing both receptors tend to respond to hormone therapy better than those who had the opposite characters. However as thought earlier, presence of visceral metastasis or larger tumors at the time of initial diagnosis dose not preclude response to hormonal manipulation. [Table: see text] No significant financial relationships to disclose.

Treatment and risk of mortality for 58,953 cases of stage 1, ER+/PR+/HER2- breast cancer in four mutually exclusive race/ethnicities.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12101-e12101
Author(s):  
Vincent Caggiano ◽  
Carol Parise
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
White Women ◽  
Cox Regression ◽  
Treatment Modalities ◽  
Her2 Breast Cancer ◽  
Risk Of Mortality ◽  
Increased Risk ◽  
Race Ethnicity ◽  
Stage 1

e12101 Background: The estrogen receptor positive (ER+), progesterone receptor positive (PR+), human epidermal growth factor 2 negative (HER2-) subtype is the most common. Cases of stage 1, ER+/PR+/HER2- are most often treated with hormone therapy alone, although this is not universal. The purpose of this study was to determine if there were differences in mortality for patients with stage 1, ER+/PR+/HER2- breast cancer given no treatment, chemotherapy alone, or both chemotherapy and hormone therapy when compared with hormone therapy alone for four mutually exclusive race/ethnicities. Methods: We identified 58,953cases of Stage 1, ER+/PR+/HER2- first primary female invasive breast cancer from the California Cancer Registry 2000-2014. Cases were stratified into white (n = 41,716), black (n = 2,310), Hispanic (n = 8,186) and Asian/Pacific Islander (API) (n = 6,741). Treatment was categorized as none, hormone therapy alone, chemotherapy alone, or both chemotherapy and hormone therapy. Kaplan Meier survival analysis and Cox Regression were used to assess the risk of mortality associated with treatment using hormone therapy alone as the reference category. Treatment was considered a risk for mortality and hazard ratios (HR) and 95% confidence intervals reported if the Wald χ2 was statistically significant (p < 0.05). Models were adjusted for age, grade, socioeconomic status, and tumor size. Separate analyses were conducted for each race/ethnicity. Results: White women, having no treatment (HR = 1.33; 1.14-1.54), or chemotherapy alone (HR = 1.49; 1.10-2.00) was associated with an increased risk of mortality. For API women, having the combination of chemotherapy and hormone therapy was associated with increased risk of mortality (HR = 2.47; 1.34-4.56). For black and Hispanic women, there was no difference in risk of morality for any combination of treatment when compared with hormone therapy. Conclusions: The effectiveness of treatment modalities for the Stage 1, ER+/ER+/HER2- subtype varies considerably by race/ethnicity.

Association of the polymorphisms CYP19 (TTTA)n in treatment response to hormone therapy based in aromatase inhibitors in breast cancer patients.

2009 ◽  
Author(s):  
B Murillo-Ortiz ◽  
R Castillo-Valenzuela ◽  
S Martínez-Garza ◽  
A Moreno-Perez ◽  
A Silva ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Treatment Response ◽  
Cancer Patients ◽  
Aromatase Inhibitors ◽  
Breast Cancer Patients

scholarly journals Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer

2015 ◽  
Vol 33 (20) ◽  
pp. 2262-2269 ◽  
Author(s):  
Wei He ◽  
Fang Fang ◽  
Catherine Varnum ◽  
Mikael Eriksson ◽  
Per Hall ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Aromatase Inhibitors ◽  
Hormone Replacement ◽  
Hormonal Treatment ◽  
Linkage Study ◽  
Adjuvant Hormone Therapy ◽  
Breast Cancer Outcomes ◽  
Drug Register ◽  
Increased Risk

Purpose To identify predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. Patients and Methods We conducted a record-linkage study based on data from Stockholm-Gotland Breast Cancer Register, Swedish Prescribed Drug Register, and self-reported questionnaire. Women diagnosed with breast cancer between 2005 and 2008 in Stockholm, Sweden, were prospectively followed for 5 years until 2013, starting from their first prescription of tamoxifen or aromatase inhibitors (N = 3,395). Results Family history of ovarian cancer (hazard ratio [HR], 1.55; 95% CI, 1.19 to 2.02); younger (< 40 years; HR, 1.39; 95% CI, 1.08 to 1.78) and older (≥ 65 years; HR, 1.15; 95% CI, 1.03 to 1.28) age; higher Charlson comorbidity index (≥ 2 v 0; HR, 1.35; 95% CI, 1.03 to 1.76); and use of analgesics (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/sedatives (HR, 1.24; 95% CI, 1.07 to 1.43), GI drugs (HR, 1.25; 95% CI, 1.08 to 1.43), and hormone replacement therapy (HR, 1.27; 95% CI, 1.08 to 1.49) were identified as baseline predictors for hormonal treatment discontinuation. Use of analgesics (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/sedatives (HR, 1.21; 95% CI, 1.07 to 1.37), antidepressants (HR, 1.22; 95% CI, 1.06 to 1.40), or GI drugs (HR, 1.27; 95% CI, 1.13 to 1.43), and switching therapy between tamoxifen and aromatase inhibitors (HR, 1.50; 95% CI, 1.23 to 1.83) during the first year of hormonal treatment were associated with increased risk of discontinuation during the next 4 years. Conclusion Predictors identified in our study can be used in developing targeted intervention to prevent adjuvant hormone therapy discontinuation and subsequently to improve breast cancer outcomes.

Sign in / Sign up

Export Citation Format

Share Document